15.21

3.26% 0.48

After Hours: 15.37 0.16 +1.05%

Intellia Therapeutics Inc (NTLA)

Overview News Price History Option Chain Financials Discussions Forecast

Intellia Therapeutics Inc stock is traded at $15.21, with a volume of 2.15M. It is up +3.26% in the last 24 hours and down -4.64% over the past month. Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Previous Close:

$14.73

Open:

$15.07

24h Volume:

2.15M

Relative Volume:

0.96

Market Cap:

$1.54B

Revenue:

$45.97M

Net Income/Loss:

$-508.80M

P/E Ratio:

-2.7857

EPS:

-5.46

Net Cash Flow:

$-382.65M

1W Performance:

+15.93%

1M Performance:

-4.64%

6M Performance:

-38.77%

1Y Performance:

-50.38%

1-Day Range:

$14.64

$15.46

1-Week Range:

$13.23

$15.46

52-Week Range:

$12.82

$34.87

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name

Intellia Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

857-285-6200

Address

40 ERIE STREET, CAMBRIDGE, MA

Employee

598

Twitter

@intelliatweets

Next Earnings Date

2024-11-07

Latest SEC Filings

NTLA's Discussions on Twitter

Compare NTLA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NTLA Intellia Therapeutics Inc	15.21	1.54B	45.97M	-508.80M	-382.65M	-5.46
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-23-24	Downgrade	Goldman	Buy → Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy
Mar-21-23	Initiated	Bernstein	Outperform
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Jan-24-23	Upgrade	Citigroup	Sell → Neutral
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-01-22	Initiated	Citigroup	Sell
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Jun-16-22	Initiated	BofA Securities	Buy
Apr-28-22	Initiated	Credit Suisse	Outperform
Feb-18-22	Initiated	William Blair	Outperform
Feb-07-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-31-22	Initiated	Cowen	Outperform
Jan-07-22	Initiated	Piper Sandler	Overweight
Oct-05-21	Initiated	Guggenheim	Buy
Sep-24-21	Initiated	Stifel	Buy
Jun-28-21	Reiterated	H.C. Wainwright	Buy
Jun-11-21	Initiated	H.C. Wainwright	Buy
May-07-21	Upgrade	ROTH Capital	Neutral → Buy
May-04-21	Initiated	RBC Capital Mkts	Outperform
Mar-04-21	Initiated	JMP Securities	Mkt Outperform
Dec-22-20	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-27-20	Initiated	Truist	Buy
Oct-14-20	Initiated	Wells Fargo	Overweight
Sep-18-20	Initiated	Goldman	Buy
Feb-28-20	Upgrade	Oppenheimer	Perform → Outperform
Feb-14-20	Downgrade	Wedbush	Outperform → Neutral
Nov-01-19	Upgrade	Raymond James	Mkt Perform → Outperform
Jul-09-19	Initiated	Robert W. Baird	Outperform
Jun-10-19	Initiated	ROTH Capital	Neutral
May-03-19	Upgrade	Wedbush	Neutral → Outperform
Apr-12-19	Initiated	Evercore ISI	Outperform
Nov-02-18	Downgrade	Wedbush	Outperform → Neutral
Oct-29-18	Initiated	Credit Suisse	Neutral
Sep-21-18	Initiated	Raymond James	Mkt Perform
May-15-18	Upgrade	Chardan Capital Markets	Neutral → Buy
Mar-08-18	Initiated	JMP Securities	Mkt Outperform
Nov-01-17	Reiterated	Jefferies	Buy
Jun-22-17	Resumed	Jefferies	Buy
Mar-28-17	Initiated	Chardan Capital Markets	Buy
Aug-05-16	Upgrade	Jefferies	Hold → Buy

View All

Intellia Therapeutics Inc Stock (NTLA) Latest News

Nov 26, 2024

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? - Benzinga

Nov 26, 2024

NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy - Yahoo Finance

Nov 26, 2024

Nov 25, 2024

Intellia Therapeutics' SWOT analysis: gene editing firm's stock faces pivotal trials - Investing.com

Nov 25, 2024

Gene-editing therapy aiding FAP patients year or more later: Trial - FAP News Today

Nov 25, 2024

Hereditary Angioedema Market Expected to Experience Major - openPR

Nov 25, 2024

Intellia Therapeutics: NTLA-2002 CRISPR-based therapy reduces rates of Hereditary Angioedema (HAE) attacks - 2 Minute Medicine

Nov 25, 2024

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - The Manila Times

Nov 25, 2024

Intellia's CRISPR Therapy Nex-Z Secures FDA RMAT Designation for Rare Disease Treatment | NTLA Stock News - StockTitan

Nov 25, 2024

Nov 22, 2024

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? - sharewise

Nov 22, 2024

Nov 21, 2024

Drug developer stocks slide further in fall, despite gains from Exelixis and Xencor - BioWorld Online

Nov 21, 2024

Equities Analysts Offer Predictions for NTLA FY2025 Earnings - MarketBeat

Nov 21, 2024

Nov 20, 2024

Intellia Therapeutics price target lowered to $55 from $76 at Barclays - MSN

Nov 20, 2024